Abstract
Background Middle East respiratory syndrome (MERS), is a zoonotic disease caused by MERS coronavirus (MERS-CoV). The purpose of this scoping review was to take stock of the empirical research evidence for MERSDCoV, map the information to priority research areas as set out in existing MERS-CoV research roadmaps, identify technical areas that received less attention and set recommendations for the advancement of MERS-CoV research.
Methods We undertook a scoping review for MERS-CoV, comprehensively searching the three databases PubMed, EMBASE, and CINAHL for studies published between 1 January 2012 and 24 January 2023. Two reviewers screened studies and extracted data using a pilot-tested screening form. We categorized studies into priority research areas outlined in existing roadmaps and summarized the evidence available for each category.
Results A total of 1,264 records were included in the review, assigned into pre-defined categories. 33% of the included records were molecular genetics studies, followed by therapeutic studies (17.6%) and pathogenesis studies (15.6%). We found that, while there has been a substantial research effort on MERS-CoV, many technical themes pertaining to the areas of animal, human, animal-human interface, and environmental research identified by FAO, WHO, and WOAH in the past have not sufficiently been addressed to date. This includes asymptomatic human cases role in transmission, human exposure risk from dromedary products, reinfection, analyses of camel value chain and production systems, and anthropological studies characterizing interactions at the animal-human interface, in addition to studies highlighting the role of environmental factors in MERS-CoV transmission.
Conclusion Our study highlights the continued need for coordinated action to better prepare for, prevent, detect, and respond to MERS-CoV. Examples include the need for enhancing collaborative surveillance, accelerating the development of MERS-CoV medical countermeasures, strengthening community protection, reducing MERS-CoV transmission at healthcare facility level and reinforcing multi-sectoral coordination using the One Health approach.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations used
- MERS-CoV
- Middle East respiratory syndrome coronavirus
- WHO
- World Health Organization
- PRISMA-ScR
- Systematic Reviews and Meta-Analyses Extension for Scoping Reviews
- BoD
- Burden of Disease
- FAO
- Food and Agriculture Organization
- WOAH
- the World Organisation for Animal Health
- R&D
- Research and Development
- CFR
- Case-Fatality Ratio
- EMR
- Eastern Mediterranean Region
